| P2093 | author name string | Amit Sharma | |
| | Amit Garg | |
| | Sandeep Bhatia | |
| | Umesh Chandra Gupta | |
| | Vaibhav Choudhary | |
| P2860 | cites work | The price of innovation: new estimates of drug development costs | Q28212140 |
| | The value of improving the productivity of the drug development process: faster times and better decisions | Q28216310 |
| | Can the pharmaceutical industry reduce attrition rates? | Q29616077 |
| | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies | Q33985780 |
| | Government regulations and the use of drugs. | Q34774101 |
| | Cutting the cost of drug development? | Q35732868 |
| | The progress and promise of molecular imaging probes in oncologic drug development | Q36318111 |
| | The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials | Q36611045 |
| | Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | Q36622291 |
| | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient | Q36732058 |
| | Designing phase 0 cancer clinical trials | Q36732115 |
| | Innovative early development regulatory approaches: expIND, expCTA, microdosing | Q37037370 |
| | Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice | Q37058731 |
| | The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials | Q37193276 |
| | Phase 0 trials: an industry perspective | Q37193278 |
| | Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies | Q37337123 |
| | The ethics of phase 0 oncology trials | Q44552692 |
| | Phase 0 clinical trials: an answer to drug development stagnation? | Q46052036 |
| | Patient perspectives on phase 0 clinical trials | Q46535690 |
| | Stability of phosphoprotein as a biological marker of tumor signaling | Q46549087 |
| | Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? | Q46607034 |
| | Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 |
| | Compressing drug development timelines in oncology using phase '0' trials | Q53208031 |
| | Risks in new drug development: approval success rates for investigational drugs | Q73924789 |
| | Slow start to phase 0 as researchers debate value | Q79760785 |
| | Participants in phase 1 oncology research trials: are they vulnerable? | Q80492927 |
| | An overview of the drug development process | Q80944811 |
| | Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) | Q81227820 |
| | Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) | Q81341430 |
| | Leveraging exploratory investigational new drug studies to accelerate drug development | Q81469375 |
| | Oncology's first Phase 0 trial | Q84191554 |
| | The cost of new drug discovery and development | Q84730346 |
| | Phase 0 Clinical Trials in Oncology: An Exploratory Methodology for Constructing a Study With Patients Undergoing Surgery for Metastatic Disease | Q85024128 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| P304 | page(s) | 13-22 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Perspectives in Clinical Research | Q15816720 |
| P1476 | title | Phase 0 clinical trials in oncology new drug development | |
| P478 | volume | 2 | |